Ergun Y - Search Results

1

The Real-Life Data of BRAF Mutation on the Treatment of Colorectal Cancer: a TOG Study.

Beypinar I, Demir H, Sakin A, Taskoylu BY, Sakalar T, Ergun Y, Korkmaz M, Ates O, Eren T, Turhal S, Artac M. Beypinar I, et al. Among authors: ergun y. J Gastrointest Cancer. 2021 Sep;52(3):932-939. doi: 10.1007/s12029-020-00514-9. J Gastrointest Cancer. 2021. PMID: 32914373

2

Common Sense Oncology: including everyone.

Ergun Y. Ergun Y. Lancet Oncol. 2023 Oct;24(10):e403. doi: 10.1016/S1470-2045(23)00359-5. Lancet Oncol. 2023. PMID: 37797641 No abstract available.

3

Comparison of the Efficacy and Safety of 3 Months of CAPOX Followed by 3 Months of Capecitabine and 6 Months of CAPOX/FOLFOX in the Adjuvant Treatment of Low-Risk Stage III Colon Cancer Treated Surgically.

Bardakci M, Demirtas Esmer D, Hafizoglu E, Yaslikaya S, Genc TB, Ozcelik M, Erdat EC, Hendem E, Buyukbayram ME, Alaca Topcu Z, Kalkan Z, Yildirim N, Celebi A, Ergun Y, Paydas S, Tatli AM, Karakas H, Koseci T, Sendur MAN. Bardakci M, et al. Among authors: ergun y. Oncology. 2023;101(11):723-729. doi: 10.1159/000531722. Epub 2023 Jun 28. Oncology. 2023. PMID: 37379817

4

Comparison of Gemcitabine monotherapy with Gemcitabine and Cisplatin combination in metastatic pancreatic cancer: a retrospective analysis.

Ergun Y, Ozdemir NY, Guner EK, Esin E, Sendur MA, Koksoy EB, Demirci NS, Eren T, Dede I, Sezer A, Engin H, Oksuzoglu B, Yalcin B, Utkan G, Zengin N, Urun Y. Ergun Y, et al. J BUON. 2018 Dec;23(7):116-121. J BUON. 2018. PMID: 30722120 Free article.

5

Drug-drug interactions in patients using tyrosine kinase inhibitors: A multicenter retrospective study.

Ergun Y, Yildirim Ozdemir N, Toptas S, Kurtipek A, Eren T, Yazici O, Sendur MA, Akinci B, Ucar G, Oksuzoglu B, Uncu D. Ergun Y, et al. J BUON. 2019 Jul-Aug;24(4):1719-1726. J BUON. 2019. PMID: 31646831 Free article.

6

KRAS codon 12 and 13 mutations may guide the selection of irinotecan or oxaliplatin in first-line treatment of metastatic colorectal cancer.

Ergun Y, Acikgoz Y, Bal O, Ucar G, Dirikoc M, Caliskan Yildirim E, Akdeniz N, Uncu D. Ergun Y, et al. Expert Rev Mol Diagn. 2019 Dec;19(12):1131-1140. doi: 10.1080/14737159.2019.1693266. Epub 2019 Nov 19. Expert Rev Mol Diagn. 2019. PMID: 31718325

7

Capecitabine plus temozolomide (CapTem): An alternative regimen to regorafenib as third-line setting in metastatic colorectal cancer?

Ergun Y, Bal O, Dogan M, Uncu D. Ergun Y, et al. J BUON. 2019 Nov-Dec;24(6):2435-2441. J BUON. 2019. PMID: 31983117 Free article.

8

The prognostic value of the prognostic nutritional index in patients with metastatic colorectal cancer.

Ucar G, Ergun Y, Acikgoz Y, Uncu D. Ucar G, et al. Among authors: ergun y. Asia Pac J Clin Oncol. 2020 Oct;16(5):e179-e184. doi: 10.1111/ajco.13328. Epub 2020 Apr 16. Asia Pac J Clin Oncol. 2020. PMID: 32301263

9

Correlation between peripheral blood inflammatory indicators and pathologic complete response to neoadjuvant chemotherapy in locally advanced breast cancer patients.

Eren T, Karacin C, Ucar G, Ergun Y, Yazici O, İmamoglu Gİ, Ozdemir N. Eren T, et al. Among authors: ergun y. Medicine (Baltimore). 2020 May 29;99(22):e20346. doi: 10.1097/MD.0000000000020346. Medicine (Baltimore). 2020. PMID: 32481414 Free article.

10

Is there any correlation among MKK4 (mitogen-activated protein kinase kinase 4) expression, clinicopathological features, and KRAS/NRAS mutation in colorectal cancer.

Dogan M, Guresci S, Acikgoz Y, Ergun Y, Kos FT, Bozdogan O, Bal O. Dogan M, et al. Among authors: ergun y. Expert Rev Mol Diagn. 2020 Aug;20(8):851-859. doi: 10.1080/14737159.2020.1784728. Epub 2020 Jul 13. Expert Rev Mol Diagn. 2020. PMID: 32552144

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

153 results

Search Page